# 1. Financial Performance ## A. Key Figures * Consolidated Revenue: ₹3,171 Mn Q3 FY'26 (+44%) · ₹8,534 Mn 9M FY'26 (+43%) * EBITDA: ₹1,083 Mn Q3 FY'26 (+75%) · ₹2,716 Mn 9M FY'26 (+75%) * **EBITDA Margin:** **34%** Q3 FY'26 (+600 bps) * PAT: ₹645 Mn Q3 FY'26 (+49%) · ₹1,655 Mn 9M FY'26 (+53%) * **PAT Margin:** **20%** Q3 FY'26 (+200 bps) · **19%** 9M FY'26 (+200 bps) ## B. Revenue Growth * **Strong YoY Growth:** Robust double-digit revenue expansion in Q3 and first 9 months, reflecting sustained demand and operating scale. * **One-Time Impact:** Q-on-Q surge in "other" segment driven by **~INR15 Cr one-time FLOP claim** reclassified into revenue; not indicative of recurring trend. ## C. EBITDA & Margins * **Margin Expansion with Caveats:** EBITDA margin reached 34% in Q3, supported by high-margin CRAM segment (60–65%) and one-time benefit; sustainable run-rate guided at **29–30%**. * **Business Model Divergence:** EBITDA margins vary significantly across segments—CRAM (60–65%), CEM (27–30%), LSM (21–23%)—highlighting CRAM as key profitability driver. * **Cost Discipline:** No gross margin benefit from recent softness in raw material prices; staff cost efficiency remains a competitive advantage. ## D. PAT & Profitability * **Bottom-Line Acceleration:** PAT growth outpaced revenue in both periods, driven by operating leverage and margin expansion. ## E. Cash Flow & Working Capital * **Working Capital Pressure:** Net working capital cycle expanded to **~160 days** from 149 days due to inventory buildup ahead of **Site 3++ and Site 5 ramp-up (March '26)**. * **Structural Intensity:** LSM business faces inherently high working capital needs due to **180–250-day payment terms with LCs**, necessary to compete with Chinese players. * **Limited CFO Disclosure:** Full 9-month cash flow from operations not disclosed; only 6-month data available. --- # 2. Segment & Revenue Mix ## A. Key Figures * **Revenue Mix:** **64%** domestic · **36%** export * **Sales Distribution (Q3 FY26):** **43%** contracts + exclusive manufacturing · **41%** large-scale manufacturing (LSM) · **8%** CRAMS * **Sectoral Revenue:** **45%** pharma & agro · **22%** oil & gas · **18%** material science * **Contract Manufacturing Revenue:** **₹135 Cr** (+QoQ) · **Baker Hughes Business:** **₹60 Cr** (+QoQ) * **Volume Growth:** **>10% QoQ** and **>25% YoY** in LSM · **10% QoQ** and **25% YoY** in pharma API intermediates ## B. CRAMS & CEM Sales * **Export-Driven Model:** Strong international footprint with over a third of revenue from exports, underpinned by growing CEM and CRAMS demand. * **Strategic Research Funding:** CRAMS projects combine client prepayments for standard work and company-funded investments in long-term strategic initiatives. ## C. Large-Scale Manufacturing * **Robust Volume Momentum:** LSM delivered strong sequential and annual volume growth, driven by key products and stable pricing. * **Product & Market Expansion:** Three new first-time-made-in-India products launched for pharma and agro sectors at **$30–$40/kg**; Site 5 enters semiconductor-grade electronic chemicals with validation batches shipped to **Japan, South Korea, and Taiwan**. * **Strategic Rebalancing:** Management is pivoting toward CEM and CRAMS due to **shorter payment cycles** and **faster inventory turnover**, signaling a shift in capital efficiency focus. ## D. Pharma & Agro Share * **Resilient Sector Demand:** Pharma and agro remains the largest end-market, with strong volume growth and pricing stabilization after trough levels. --- # 3. Manufacturing & Capacity ## A. Key Figures * **Capex (9M):** **₹500 Cr** CWIP for Site 3++ and Site 5 at Panoli * **Remaining CWIP:** **₹200 Cr** at Panoli · **₹250–260 Cr** at Site 3++ * **Capacity Utilization:** 76% Site 2 · 70% Site 3 · 49% Site 4 * **Projected FY+1 Utilization:** **45–50%** Site 3++ · **35–40%** Site 5 ## B. Site 3++ & Site 5 Progress * **Imminent Commercial Launch:** Site 3++ and first two blocks of Site 5 have completed construction and trials, with commercial production set to begin shortly. * **Strategic Expansion:** Ongoing capex and site expansions across Site 1, Site 3, and Site 5 are backed by a strong CRAMS pipeline and exclusive partnerships with global innovators. ## C. Capacity Utilization * **Efficiency Optimization:** Repurposing a production line at Site 3 for a CEM contract enhances utilization and accelerates capacity deployment. * **Sufficient Near-Term Capacity:** Existing infrastructure can absorb upcoming contract demand without requiring accelerated Site 5 rollout. ## D. Fungible Plant Design * **Flexible Manufacturing:** Plants are designed as fungible, multipurpose units under the **8x8 metrics framework**, enabling rapid repurposing across core competencies. * **Supply Resiliency:** Redundant, geographically dispersed sites (Sites 2–5) support multi-site supply chains to mitigate operational risks. --- # 4. Product & R&D Pipeline ## A. Key Figures * **Converge Polyol Capacity:** **500 TPA** current · **2,000 TPA (2 KTA)** planned * **Addressable Market:** **850 KTA** for Converge polyol in case industry * **R&D Projects:** **50** ongoing · **100–200** targeted over time * **R&D Expansion:** **+20 fume hoods** (short-term) · **+150 fume hoods, 15 labs** (long-term) ## B. New Product Launches * **Strategic Clarity:** Low dielectric resin targets high-speed PCB substrates and electronic-grade composites—**not photoresist applications**—highlighting focused material science positioning. ## C. Converge Polyol Update * **Commercial Momentum:** Converge polyol shows strong market traction with expanding customer trials and initial orders, progressing toward FY2026 targets despite macro headwinds. * **Scalability Roadmap:** Company on track to achieve **2 KTA capacity within three years**, with phased expansion contingent on market adoption. * **Market Opportunity:** Targets a multi-hundred-kiloton addressable market, positioning for long-term scale given current 500 TPA base. * **Pipeline Readiness:** Electrolyte additive products remain fully developed and scalable, awaiting improved market conditions for launch. ## D. R&D Expansion Plans * **Capacity Constraints:** Site 1 R&D center is fully utilized, driving dual-phase expansion to enhance engineering and scale-up capabilities. * **Infrastructure Buildout:** Major R&D expansion underway with **NMR spectroscopy** and advanced labs to strengthen non-pharma innovation in oil & gas and material sciences. * **Spending Commitment:** R&D expenses rose significantly in first 9 months, reflecting intensified focus on strategic sectors and technology development. ## E. Ongoing R&D Projects * **Leadership Oversight:** All 50 projects led by Aman Desai and CTO Jim Ringer, with direct integration into pilot and production operations. * **Innovation Culture:** R&D philosophy embraces experimental failure as a pathway to innovation, supporting high-risk, high-reward project outcomes. * **Pipeline Depth:** Expectation of **3–4 Milliken-scale molecules** to mature into significant contracts within 1–3 years, reinforcing growth visibility. * **Baker Hughes Collaboration:** **7–8 additional products** in research and scale-up phase, though market size remains undisclosed. --- # 5. Customer & Contract Metrics ## A. Key Figures * **Otsuka Contract Value:** **₹35–40 Cr** expected in FY26 * **Site 4 Sales:** **₹60 Cr** (up from ₹50 Cr in Q2 FY26) (+20% QoQ) * **New Clients Added:** **5** marquee clients in the quarter ## B. Baker Hughes Growth * **Sustained Momentum:** Baker Hughes revenue shows strong sequential growth, with stable run rate through FY26 and expansion expected in FY27 via broader product rollout and increased wallet share. * **Strategic Deepening:** Relationship evolving into a long-term, low-cost strategic partnership with India-based manufacturing, targeting decades-long engagement across oilfield services. * **Execution Confidence:** High client trust in innovation and execution enables single-supplier model, driven by IP protection needs and transparent collaboration. ## C. Milliken & Otsuka Deals * **Commercialization Timeline:** Milliken partnership set for Q1 FY27 commercial launch, with Site 3+ production nearing start; Otsuka contract on track for targeted revenue delivery. * **Exclusive CEM Wins:** Secured exclusive manufacturing deal in electronics and a significant European material science contract expected to scale rapidly within one year. ## D. New Client Additions * **Robust Client Acquisition:** Added 5 high-profile clients in the quarter, supported by global outreach and referrals, with strong pipeline conversion into commercial projects. * **Global Expansion Momentum:** Accelerated deal finalization with major European players reflects growing demand for reliable, innovation-led manufacturing partners. ## E. Long-Term Contracts * **Structural Advantage:** Client relationships underpinned by 5–10 year minimum contracts with auto-renewal and transparent, collaborative pricing—enabling **20-year+ strategic partnerships**. * **Win-Win Commercial Model:** Annual price reviews based on open-cost platform ensure mutual alignment on capex, opex, and profitability, reducing pricing pressure. --- # 6. Risks & Market Factors ## A. China Pricing Pressure * **Competitive Edge in India:** Indian manufacturing provides stable and favorable process economics, enhancing Aether’s competitiveness versus Western peers facing high costs. * **Project Paused Due to China Price War:** Partnership with major global Li-ion battery producer on electrolyte additives halted as **aggressive price drops in China** rendered the project uneconomical. * **Near-Term Visibility on LSM Pricing:** No current price impact in LSM segment from China; potential shifts expected within **2 to 3 weeks** post-holidays amid anti-dumping dynamics. ## B. Raw Material Volatility * **Supply Disruptions Boost Outsourcing Demand:** European chemical plant shutdowns are accelerating demand for reliable Indian manufacturing partners. --- # 7. Guidance & Outlook ## A. Key Figures * **Revenue Target Mix:** **70%** from CRAMS and CEM combined · **30%** from large-scale manufacturing * **Capex Forecast:** **₹450–500 Cr** full-year expectation (revised down from ₹550–600 Cr) * **Site 3++ Capex:** **₹260 Cr** expected investment ## B. Revenue Strategy & Client Outlook * **Strategic Revenue Mix:** Clear pivot toward CRAMS and CEM as core growth engines, with manufacturing playing a smaller, targeted role. * **Client Momentum:** Positive trajectory with key partners like Baker Hughes affirmed, despite absence of formal forward guidance. ## C. Capex & Capacity Development * **Capex Discipline:** Full-year spend revised downward, reflecting improved capital efficiency or pacing adjustments across projects. * **Converge Polyol Expansion:** Capacity ramp-up delayed but on track for recovery by **FY2026–FY2027**, with growing market acceptance broadening addressable demand.